Critical Safety Warning: Never Obtain GLP-1 from Unregulated Online Sources
The FDA has documented multiple hospitalizations and serious adverse events from counterfeit semaglutide products sold online without prescriptions — often through social media, offshore websites, and unregulated "peptide" suppliers. These products are not compounded medications; they are uncontrolled chemical substances of unknown purity and concentration. Compounded GLP-1 medications must only be obtained through a licensed U.S. compounding pharmacy or 503B facility with a valid prescription from a licensed U.S. healthcare provider. If a source does not require a prescription, it is not legitimate.
Understanding Compounding Regulations
The legal framework for compounded GLP-1 medications is defined by the Drug Quality and Security Act (DQSA) and FDA shortage policies. Understanding these distinctions is essential for evaluating the legitimacy and quality of any compounded semaglutide source.
503A Patient-Specific Compounding Pharmacies
503A compounding pharmacies are state-licensed facilities that prepare customized medication formulations on a patient-specific basis — meaning each prescription must be for an identified individual patient. They operate under USP standards and state pharmacy board oversight. During an FDA-declared shortage of brand-name GLP-1 medications, 503A pharmacies can legally compound semaglutide. Quality, potency, and sterility testing practices vary significantly between 503A pharmacies — making PCAB accreditation the most reliable proxy for quality assurance when evaluating a 503A facility.
State-Licensed503B Outsourcing Facilities (FDA-Registered)
503B outsourcing facilities are FDA-registered and operate under Current Good Manufacturing Practice (CGMP) requirements — the same standards applied to pharmaceutical manufacturers. They can produce larger batches of compounded medications for distribution to licensed healthcare providers and patients without individual patient-specific prescriptions. Many leading GLP-1 telehealth platforms partner exclusively with 503B facilities for their compounded semaglutide programs, citing the enhanced quality assurance standards. 503B facility registration can be verified directly on the FDA website.
FDA-RegisteredPCAB Accreditation — The Quality Gold Standard
PCAB (Pharmacy Compounding Accreditation Board) accreditation is the voluntary quality standard that distinguishes the highest-quality compounding pharmacies from the field. PCAB-accredited pharmacies undergo rigorous on-site inspections evaluating beyond-use dating, potency testing, sterility assurance, cleanroom standards, and quality management systems. For GLP-1 patients evaluating compounding options, PCAB accreditation is the single most important quality indicator to look for. The PCAB accreditation lookup is publicly available at pcab.org — verify any compounding pharmacy before placing an order.
Highest QualityFDA Shortage Regulations — When Compounding Is Legal
Compounding of FDA-approved drug products is generally restricted under federal law — but compounding pharmacies may legally compound semaglutide when the FDA places the branded product on its Drug Shortage List. The FDA has maintained semaglutide on shortage lists for extended periods, enabling 503A and 503B facilities to produce compounded versions legally during that time. Patients should stay informed about the current shortage status, as the regulatory landscape can change and affect the legal status of compounded GLP-1 availability. Your telehealth provider should be able to advise on current compliance status.
Shortage-DependentQuality & Safety Standards
Not all compounded semaglutide is created equal. Understanding how to evaluate quality — potency testing, sterility, stability, and certificates of analysis — helps patients make informed decisions about the safety of their compounded medication.
Potency & Sterility Testing
Reputable compounding pharmacies test each batch of compounded semaglutide for potency (confirming the stated dose is present), sterility (confirming no microbial contamination), and endotoxins (confirming the absence of pyrogens that cause fever and inflammation). Ask any compounding pharmacy or telehealth platform whether their medication is tested by an independent third-party laboratory — the answer is a reliable quality signal. Pharmacies that cannot or will not provide testing documentation should be avoided. Third-party testing significantly increases confidence in medication quality.
Third-Party TestingStability & Storage Requirements
Compounded semaglutide requires refrigerated storage (36–46°F / 2–8°C) for most formulations, with some lyophilized (freeze-dried) products having different requirements. Shipping methods matter — ensure your compounding pharmacy ships with cold packs and insulated packaging, particularly during summer months or to warm-climate states like Florida, Texas, Arizona, and California. Once received, follow storage instructions precisely. Improper storage degrades semaglutide potency rapidly, resulting in reduced effectiveness and potential safety concerns. Your prescribing provider should provide written storage and handling instructions with each shipment.
Cold Chain RequiredCertificates of Analysis (COA)
A Certificate of Analysis (COA) is a laboratory document that certifies the test results for a specific batch of compounded medication — confirming potency, sterility, and purity within acceptable ranges. Patients receiving compounded semaglutide have the right to request a COA for their medication lot. Reputable 503B facilities and PCAB-accredited 503A pharmacies make COAs readily available. If a compounding pharmacy cannot provide a COA upon request, this is a significant red flag. Reviewing the COA is the most direct way for patients to verify the quality of their compounded GLP-1 medication.
Request AlwaysSourcing, Pricing & Access
The dramatic price difference between compounded and brand-name GLP-1 medications has made treatment accessible to millions of patients who would otherwise be priced out — but understanding how pricing works and what telehealth partnerships mean for quality helps patients make informed comparisons.
Telehealth Partnerships with 503B Facilities
Many major GLP-1 telehealth platforms — including Hims & Hers, Ro, and others — partner directly with FDA-registered 503B outsourcing facilities to supply compounded semaglutide to their patients. These partnerships typically involve quality agreements that hold the 503B facility to defined testing and manufacturing standards. When evaluating a telehealth platform's compounded GLP-1 offering, ask specifically whether they use a 503B-registered facility and whether you can verify that registration on the FDA website. Platforms that are transparent about their pharmacy partnerships are generally operating with higher quality standards.
Verified PartnershipsPricing Breakdown — Compounded vs. Brand Name
Compounded semaglutide typically costs $200–$500 per month, depending on dose, pharmacy, and whether purchased through a telehealth subscription or directly. This compares to $1,200–$1,400/month list price for brand-name Wegovy and $900–$1,000 for Ozempic — a price differential of 60–80%. For the estimated 90% of patients whose insurance does not cover GLP-1 medications for weight management, compounded options have been the only financially accessible pathway. Pricing varies by dose (maintenance doses cost more than starting doses) and by whether the telehealth consultation fee is bundled into the monthly price.
60–80% Less Than BrandMicrodosing Protocols
Some telehealth providers and compounding pharmacies offer microdosing protocols — lower doses of semaglutide (0.1–0.5mg weekly) for patients seeking metabolic benefits, appetite modulation, or modest weight loss without full therapeutic dosing. Microdosing is not FDA-approved for any specific indication but has a growing following among health-optimization-focused patients in major markets. Compounding pharmacies can prepare customized lower-dose vials that are not available in branded formulations, giving prescribing physicians flexibility in dose titration. Discuss the clinical rationale thoroughly with your prescribing provider before pursuing microdosing protocols.
Customized DosingHow to Verify a Compounding Pharmacy's Credentials
Before obtaining compounded semaglutide from any pharmacy, verify: (1) State pharmacy board license — search your state's pharmacy board website by pharmacy name; (2) 503B registration — search the FDA's 503B Outsourcing Facility database at fda.gov; (3) PCAB accreditation — search the public directory at pcab.org; (4) Request a Certificate of Analysis for the medication batch; (5) Confirm the pharmacy requires a valid prescription from a U.S.-licensed provider. A pharmacy that passes all five checks is operating at the highest standards of the compounding industry.
PCAB-Accredited Compounding Pharmacies Nationwide
PCAB-accredited compounding pharmacies and FDA-registered 503B outsourcing facilities serve patients across most U.S. states, with telehealth platform partners shipping compounded GLP-1 medications nationwide. Patients in all 50 states — including rural areas of Montana, Wyoming, Alaska, and South Dakota — can access compounded semaglutide through telehealth platforms that partner with licensed 503B facilities. Verify any pharmacy's credentials using the FDA 503B database and PCAB accreditation directory before obtaining compounded GLP-1 medications.